UBS analyst Ashwani Verma increased the price target for Teva Pharmaceutical Industries Ltd (NYSE:TEVA) to $30 from the previous $28 while keeping a Buy rating on the shares. Verma highlighted Teva as ...

Bank of America Securities analyst Jason Gerberry has reiterated their bullish stance on TEVA stock, giving a Buy rating on January 21.Invest ...

Diversify Advisory Services LLC raised its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) by 2.5% during the fourth quarter, according to its most recent ...

The US Food and Drug Administration (FDA) is warning about the risk of a rare but serious allergic reaction with the medicine ...

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a ...

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the eight brokerages that are covering the stock, ...

Teva Pharmaceutical Industries Ltd (TEVA) stock saw a decline, ending the day at $20.44 which represents a decrease of $-0.50 or -2.39% from the prior close of $20.94. The stock opened at $20.95 and ...

Headlines,Teva Pharmaceutical Industries Limited, (NYSE:TEVA),remains a prominent entity in the pharmaceutical sector, with ...

Teva partners with Klinge Biopharma and Formycon to commercialize FYB203, an Eylea biosimilar, as Ahzantive in Europe and ...

Timing Trades in Teva Pharmaceutical Industries Limited American Depositary Shares TEVA can be Risky if you Don't Have ...

Teva Pharmaceutical Industries Ltd (TEVA) stock saw a decline, ending the day at $20.94 which represents a decrease of $-0.55 or -2.56% from the prior close of $21.49. The stock opened at $21.27 and ...

Catalyst Pharmaceuticals, Inc. has announced a settlement agreement with Teva Pharmaceuticals, resolving the patent ...